These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 12800600)
1. Irinotecan: promising activity in the treatment of malignant glioma. Reardon DA; Friedman HS; Powell JB; Gilbert M; Yung WK Oncology (Williston Park); 2003 May; 17(5 Suppl 5):9-14. PubMed ID: 12800600 [TBL] [Abstract][Full Text] [Related]
2. The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. Friedman HS; Keir ST; Houghton PJ Cancer; 2003 May; 97(9 Suppl):2359-62. PubMed ID: 12712457 [TBL] [Abstract][Full Text] [Related]
3. O6-benzylguanine-mediated enhancement of chemotherapy. Friedman HS; Keir S; Pegg AE; Houghton PJ; Colvin OM; Moschel RC; Bigner DD; Dolan ME Mol Cancer Ther; 2002 Sep; 1(11):943-8. PubMed ID: 12481416 [TBL] [Abstract][Full Text] [Related]
4. Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts. Castellino RC; Elion GB; Keir ST; Houghton PJ; Johnson SP; Bigner DD; Friedman HS Cancer Chemother Pharmacol; 2000; 45(4):345-9. PubMed ID: 10755324 [TBL] [Abstract][Full Text] [Related]
5. Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Reardon DA; Quinn JA; Rich JN; Gururangan S; Vredenburgh J; Sampson JH; Provenzale JM; Walker A; Badruddoja M; Tourt-Uhlig S; Herndon JE; Dowell JM; Affronti ML; Jackson S; Allen D; Ziegler K; Silverman S; Bohlin C; Friedman AH; Bigner DD; Friedman HS Neuro Oncol; 2004 Apr; 6(2):134-44. PubMed ID: 15134628 [TBL] [Abstract][Full Text] [Related]
7. Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials. Goldberg RM; Erlichman C Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):59-63. PubMed ID: 9726093 [TBL] [Abstract][Full Text] [Related]
8. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Turner CD; Gururangan S; Eastwood J; Bottom K; Watral M; Beason R; McLendon RE; Friedman AH; Tourt-Uhlig S; Miller LL; Friedman HS Neuro Oncol; 2002 Apr; 4(2):102-8. PubMed ID: 11916501 [TBL] [Abstract][Full Text] [Related]
9. [Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials]. Mitry E; Ducreux M; Rougier P Bull Cancer; 1998 Dec; Spec No():38-42. PubMed ID: 9932083 [TBL] [Abstract][Full Text] [Related]
10. O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma. Rhines LD; Sampath P; Dolan ME; Tyler BM; Brem H; Weingart J Cancer Res; 2000 Nov; 60(22):6307-10. PubMed ID: 11103789 [TBL] [Abstract][Full Text] [Related]
11. Temozolomide in combination with other cytotoxic agents. Prados M Semin Oncol; 2001 Aug; 28(4 Suppl 13):24-33. PubMed ID: 11550136 [TBL] [Abstract][Full Text] [Related]
12. Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma. Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Gururangan S; Sampson JH; McLendon RE; Herndon JE; Friedman HS Cancer; 2009 Jul; 115(13):2964-70. PubMed ID: 19402172 [TBL] [Abstract][Full Text] [Related]
13. Preclinical and clinical trials of topoisomerase inhibitors. Saijo N Ann N Y Acad Sci; 2000; 922():92-9. PubMed ID: 11193928 [TBL] [Abstract][Full Text] [Related]
14. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Rougier P; Van Cutsem E; Bajetta E; Niederle N; Possinger K; Labianca R; Navarro M; Morant R; Bleiberg H; Wils J; Awad L; Herait P; Jacques C Lancet; 1998 Oct; 352(9138):1407-12. PubMed ID: 9807986 [TBL] [Abstract][Full Text] [Related]
15. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations. Cerea G; Vaghi M; Ardizzoia A; Villa S; Bucovec R; Mengo S; Gardani G; Tancini G; Lissoni P Anticancer Res; 2003; 23(2C):1951-4. PubMed ID: 12820485 [TBL] [Abstract][Full Text] [Related]
16. FDA approves irinotecan as first-line therapy for colorectal cancer. Oncology (Williston Park); 2000 May; 14(5):652, 654. PubMed ID: 10853457 [No Abstract] [Full Text] [Related]
17. Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group. Buckner JC; Reid JM; Wright K; Kaufmann SH; Erlichman C; Ames M; Cha S; O'Fallon JR; Schaaf LJ; Miller LL Cancer; 2003 May; 97(9 Suppl):2352-8. PubMed ID: 12712456 [TBL] [Abstract][Full Text] [Related]
18. US pivotal studies of irinotecan in colorectal carcinoma. Pitot HC Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):48-53. PubMed ID: 9726091 [TBL] [Abstract][Full Text] [Related]
19. Irinotecan (CPT-11) in patients with advanced colorectal cancer previously treated with 5-fluorouracil-based chemotherapy. Aravantinos G; Skarlos DV; Kosmidis P; Georgoulias V; Sgouros I; Bafaloukos D; Androulakis N; Florou S; Fountzilas G Crit Rev Oncol Hematol; 1999 Dec; 32(3):209-19. PubMed ID: 10633850 [No Abstract] [Full Text] [Related]
20. Experience with irinotecan for the treatment of malignant glioma. Vredenburgh JJ; Desjardins A; Reardon DA; Friedman HS Neuro Oncol; 2009 Feb; 11(1):80-91. PubMed ID: 18784279 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]